MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Capivasertib

CAS No. : 1143532-39-1

MCE 站：Capivasertib

产品活性：Capivasertib (AZD5363) 是一种口服有效的 pan-AKT 激酶抑制剂，抑制 Akt1，Akt2 和 Akt3，IC₅₀ 分别为 3，7 和 7 nM。

研究领域：PI3K/Akt/mTOR  |  Autophagy

作用靶点：Akt  |  Autophagy

In Vitro: Capivasertib, a novel pyrrolopyrimidine-derived compound, inhibits all AKT isoforms with a potency of 10 nM or less. Capivasertib inhibits phosphorylation of these substrates with an IC₅₀ value of 0.06 to 0.76 μM in the 3 cell lines. Capivasertib effectively inhibits phosphorylation of S6 ａnd 4E-BP1 in these cell lines, whereas it increases phosphorylation of AKT at both ser⁴⁷³ ａnd thr³⁰⁸. In BT474c cells, Capivasertib induces FOXO3a nuclear translocation with EC₅₀ value of 0.69 μM; a concentration of 3 μM is sufficient to almost completely localize FOXO3a to the nucleus. AZD5363Capivasertibhibitor MK-2206 is much less active (IC₅₀>30 μM).

In Vivo: Oral dosing of Capivasertib (AZD5363) to nude mice causes dose- ａnd time-dependent reduction of PRAS40, GSK3β, ａnd S6 phosphorylation in BT474c xenografts (PRAS40 phosphorylation EC₅₀ ~0.1 μM total plasma exposure), reversible increases in blood glucose concentrations, ａnd dose-dependent decreases in 2[¹⁸F]fluoro-2-deoxy-D-glucose (¹⁸F-FDG) uptake in U87-MG xenografts. Chronic oral dosing of Capivasertib caused dose-dependent growth inhibition of xenografts derived from various tumor types, including HER2⁺ breast cancer models. Capivasertib also significantly enhances the antitumor activity of RP-56976 ａnd GW572016 in breast cancer xenografts.

相关产品：Drug Repurposing Compound Library Plus  |  Clinical Compound Library Plus  |  Bioactive Compound Library Plus  |  Kinase Inhibitor Library  |  PI3K/Akt/mTOR Compound Library  |  Stem Cell Signaling Compound Library  |  Anti-Cancer Compound Library  |  Clinical Compound Library  |  Autophagy Compound Library  |  Anti-Aging Compound Library  |  Drug Repurposing Compound Library  |  Differentiation Inducing Compound Library  |  Diabetes Related Compound Library  |  Oxygen Sensing Compound Library  |  Anti-COVID-19 Compound Library  |  Glycolysis Compound Library  |  Cytoskeleton Compound Library  |  Orally Active Compound Library  |  Glutamine Metabolism Compound Library  |  Anti-Breast Cancer Compound Library  |  Anti-Lung Cancer Compound Library  |  Anti-Pancreatic Cancer Compound Library  |  Anti-Blood Cancer Compound Library  |  Honokiol  |  GSK-690693  |  Artemisinin  |  Perifosine  |  Oridonin  |  Guggulsterone  |  Miransertib  |  SU6656  |  Triciribine  |  Scutellarin  |  Isobavachalcone  |  Recilisib  |  Deguelin  |  A-674563 hydrochloride  |  Miltefosine  |  YS-49  |  α-Linolenic acid  |  Urolithin B  |  Pachymic acid  |  3CAI  |  Polyphyllin I  |  1,3-Dicaffeoylquinic acid  |  Esculetin  |  Licochalcone E  |  Cyclovirobuxine D  |  GSK2110183 analog 1 hydrochloride  |  SC66  |  Akt1 ａnd Akt2-IN-1  |  Arnicolide D

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。